CRISPR Therapeutics AG
CRISPR Therapeutics AG is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on November 2, 2026, a projected date rather than a confirmed one. There are 5 upcoming events on record.
Cash runway is approximately 65.1 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
Across 7 concluded trials, 29% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 2, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| June 15, 2027 | A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias | Trial Milestone | Phase 1 |
| July 1, 2028 | A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension | Trial Milestone | Phase 1/Phase 2 |
| January 15, 2030 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | Trial Milestone | Phase 1/Phase 2 |
| December 15, 2033 | Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease | Trial Milestone | Phase 1/Phase 2 |
Track CRSP alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open CRSP in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.